Financial Data and Key Metrics Changes - In Q4 2025, product revenue reached $1.5 billion, representing a 32% year-over-year growth [24] - BRUKINSA global revenues totaled $1.1 billion in Q4, growing 38%, with full-year revenues of $3.9 billion, a 49% increase [24] - Gross margin improved to 87% from approximately 84% in the prior year, reflecting favorable product mix and cost efficiencies [26][27] - Operating expenses grew by 12% to $4.2 billion, with income from operations totaling $447 million, showcasing profitability [28] Business Line Data and Key Metrics Changes - BRUKINSA established itself as the leading BTK inhibitor globally, with U.S. sales of $845 million in Q4, driven by a volume growth of approximately 30% [24] - TEVIMBRA reported an 18% increase in revenue, reflecting continued market leadership in China [25] - In-licensed products showed a 9% year-over-year growth, contributing to solid execution across geographies [25] Market Data and Key Metrics Changes - The U.S. remains the largest market, generating $850 million with a year-over-year growth of 38% [25] - China revenue totaled $399 million, an 11% increase compared to Q4 2024, supported by market leadership of TEVIMBRA and BRUKINSA [26] - Europe contributed $174 million, with a 53% year-over-year growth, as BRUKINSA continues its launch trajectory [26] Company Strategy and Development Direction - The company aims to deepen its leadership in CLL and expand across hematological malignancies and solid tumors [37] - Plans to advance one to two cornerstone immunology assets towards registration, indicating a strategic shift towards immunology [37] - The company believes it can move faster and achieve better outcomes across other diseases, leveraging its foundational CLL franchise [37] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the differentiated value proposition of BRUKINSA, emphasizing its safety profile and long-term efficacy [52] - The company anticipates continued strong demand growth in the U.S. with stable net pricing, projecting 2026 revenue between $6.2 billion and $6.4 billion [30] - Management highlighted the importance of addressing unmet medical needs with new product launches, including sonrotoclax and zanidatamab [30] Other Important Information - The company reported a non-recurring $40 million equity investment impairment in Q4, impacting net income [28] - Free cash flow was over $940 million for the full year 2025, indicating strong cash generation [29] - The company is optimistic about the potential of its new pipeline assets, including a proprietary off-the-shelf iPSC-derived gamma delta T-cell therapy [40] Q&A Session Summary Question: Potential net pricing development in the BTK inhibitor market - Management emphasized BRUKINSA's differentiated value proposition and its best-in-class status, which should mitigate pricing pressures from competitors entering the market [51][52] Question: Guidance assumptions regarding competition from AV or Jaypirca - Management noted that AV's clinical profile does not meet the standards for treatment in CLL, and they remain confident in BRUKINSA's position [56] Question: Strategy for immunology pipeline development - The company aims to identify 1 or 2 cornerstone assets in immunology over the next few years, with a focus on being first or best in class [61][63] Question: Impact of ZS becoming the fixed duration regimen of choice on BRUKINSA revenues - Management explained that the combination of sonrotoclax and zanubrutinib would open up a new market segment, potentially expanding overall market share [68][70] Question: Update on BTK degrader approval timeline - Management confirmed that there has been no change in the timing for the BTK degrader's approval, with plans to interact with the FDA midyear [76]

Financial Data and Key Metrics Changes - In Q4 2025, product revenue reached $1.5 billion, representing a 32% year-over-year growth [23] - BRUKINSA global revenues totaled $1.1 billion in Q4, growing 38%, with full-year revenues of $3.9 billion, a 49% increase [23] - Gross margin improved to 87% from approximately 84% in the prior year, driven by favorable product mix and cost efficiencies [25] - Operating expenses grew by 12% to $4.2 billion, while income from operations totaled $447 million, indicating profitability [26] - Non-GAAP net income for 2025 was $918 million, translating to diluted non-GAAP earnings per ADS of $8.09 [27] Business Line Data and Key Metrics Changes - BRUKINSA established itself as the leading BTK inhibitor globally, capturing approximately half of the continuous BTK segment of the market [21] - TEVIMBRA reported an 18% increase in revenue, reflecting continued market leadership in China [24] - In the U.S., BRUKINSA sales in Q4 were $845 million, driven by volume growth of approximately 30% [23] - China revenue totaled $399 million, an 11% increase, supported by TEVIMBRA and BRUKINSA's market leadership [25] Market Data and Key Metrics Changes - The CLL market is valued at $12 billion and is growing due to therapeutic innovations [5] - The U.S. remains the largest market for BRUKINSA, generating $850 million with year-over-year growth of 38% [24] - Europe contributed $174 million, with 53% year-over-year growth, as BRUKINSA continues its launch trajectory [25] - Rest of world markets grew 74%, driven by market expansion and new launches [25] Company Strategy and Development Direction - The company aims to deepen its leadership in CLL with three foundational medicines and expand into hematological malignancies and solid tumors [35] - Plans include advancing one to two potential cornerstone immunology assets towards registration [35] - The company is focused on developing a more efficacious, time-limited regimen that addresses unmet needs in the CLL market [19] - The strategy includes leveraging the differentiated clinical data of BRUKINSA to maintain a competitive edge [48] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the continued demand for BRUKINSA and stable net pricing in the U.S. market [28] - The company anticipates revenue growth between $6.2 billion and $6.4 billion for 2026, driven by global expansion and new product launches [29] - Management highlighted the importance of clinical data in establishing BRUKINSA as a best-in-class product [48] Other Important Information - The company initiated three phase 3 studies for its BTK degrader and made significant progress in solid tumors [33] - The company is advancing a proprietary off-the-shelf iPSC-derived gamma delta T-cell therapy, which is designed to overcome limitations of existing therapies [38] - The global clinical development superhighway is a core competitive advantage, enabling faster and more efficient clinical trials [42] Q&A Session Summary Question: Can you comment on potential net pricing development in the BTK inhibitor market? - Management emphasized BRUKINSA's differentiated value proposition and its best-in-class status, which supports its pricing strategy despite competition [47][48] Question: What are the assumptions regarding competition from AV or Jaypirca? - Management expressed confidence in BRUKINSA's clinical profile and its positioning against competitors, noting that AV does not meet the necessary treatment standards [50][52] Question: Can you clarify the strategy for immunology beyond hematology and solid tumors? - Management indicated that about 20% of their assets are focused on immunology, with plans to identify one or two cornerstone assets in the next 2-3 years [57][59] Question: How will ZS impact continuous BRUKINSA revenues if it becomes the fixed duration regimen of choice? - Management explained that the combination of sonrotoclax and zanubrutinib would open up a new market segment, expanding overall market opportunities rather than cannibalizing existing revenues [61][63] Question: What is the status of the BTK degrader and its potential approval timeline? - Management confirmed that there has been no change in the timing for the BTK degrader's approval, with plans to interact with the FDA midyear [70][71]

Core Insights - BeOne Medicines Ltd. announced new data on sonrotoclax, a next-generation BCL2 inhibitor, showing significant clinical benefits as both a monotherapy and in combination therapies for B-cell malignancies, particularly at the 67th American Society of Hematology Annual Meeting [1][2] Summary by Category Clinical Data - Sonrotoclax demonstrated an overall response rate (ORR) of 52.4% in patients with relapsed/refractory mantle cell lymphoma (MCL), with a complete response (CR) rate of 15.5% in a Phase 1/2 study [3] - The median duration of response (DOR) was 15.8 months, with a median time to response (TTR) of 1.9 months and a median progression-free survival (PFS) of 6.5 months [4] - In combination therapies, sonrotoclax plus zanubrutinib achieved a 100% ORR in 135 efficacy-evaluable patients, with a CR/CRi rate of 55% [7] Safety and Tolerability - Treatment with sonrotoclax monotherapy was generally well tolerated, with manageable adverse events; the most common grade 3 treatment-emergent adverse events included neutropenia (19.1%), infections (16.5%), and pneumonia (10.4%) [5] - The combination therapies also showed good tolerability, with no treatment-emergent adverse events leading to death or significant complications [13][14] Regulatory Status - Sonrotoclax is under Priority Review by the U.S. Food and Drug Administration (FDA) for potential accelerated approval, having received Breakthrough Therapy Designation and Fast Track Designation for MCL and other conditions [5][17] Market Potential - Sonrotoclax could become the first BCL2 inhibitor approved for relapsed/refractory MCL in the U.S., with the potential to transform treatment outcomes for patients with limited options [3][6]